Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vivo Bio TechBOM:511509 -0.08%64 Return-on-Tangible-Equity is 1.79% as of Jun. 2026, which is 87% below its 10-year median of 13.68. GuruFocus rates BOM:511509 with a GF Score™ of 64/100 and a GF Value™ of ₹30.45 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,200 Biotechnology companies, Vivo Bio Tech ranks better than 73.92% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Vivo Bio Tech's annualized net income for the quarter that ended in Jun. 2026 was ₹7.5 Mil. Vivo Bio Tech's average shareholder tangible equity for the quarter that ended in Jun. 2026 was ₹419.3 Mil. Therefore, Vivo Bio Tech's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2026 was 1.79%.
The historical rank and industry rank for Vivo Bio Tech's Return-on-Tangible-Equity or its related term are showing as below:
BOM:511509'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -5.01 Med: 13.68 Max: 46.79
Current: -5.01
During the past 13 years, Vivo Bio Tech's highest Return-on-Tangible-Equity was 46.79%. The lowest was -5.01%. And the median was 13.68%.
BOM:511509's Return-on-Tangible-Equity is ranked better than 73.92% of 1200
companies
in the Biotechnology industry
Industry Median: -42.435
vs BOM:511509: -5.01
Vivo Bio Tech (BOM:511509) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Vivo Bio Tech Return-on-Tangible-Equity Related Terms
Vivo Bio Tech Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Vivo Bio Tech's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:511509 vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Vivo Bio Tech's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivo Bio Tech Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vivo Bio Tech's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Vivo Bio Tech's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 1.79% mean?
Vivo Bio Tech (BOM:511509) has a Return-on-Tangible-Equity of 1.79% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Vivo Bio Tech and its competitors. This is 87% below median its historical median of 13.68. According to the industry distribution chart, Vivo Bio Tech ranks #313 out of 1200 companies in the Biotechnology industry, placing it in the top 26.1%.
Is Vivo Bio Tech's Return-on-Tangible-Equity too high?
Vivo Bio Tech's current Return-on-Tangible-Equity of 1.79% is 87% below median its 10-year median of 13.68. Based on the distribution chart, Vivo Bio Tech ranks #313 out of 1200 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Vivo Bio Tech has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vivo Bio Tech's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vivo Bio Tech ranks #313 out of 1200 companies for Return-on-Tangible-Equity. This puts Vivo Bio Tech in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Vivo Bio Tech and its competitors. Vivo Bio Tech's current Return-on-Tangible-Equity is 1.79%, which is 87% below median its own 10-year median of 13.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivo Bio Tech stock overvalued right now?
Based on GuruFocus' analysis, Vivo Bio Tech (BOM:511509) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹30.45, compared to a current price of ₹23.57 — trading 22.6% below its estimated fair value. The current Return-on-Tangible-Equity is 1.79%, which is 87% below median its 10-year median of 13.68. Vivo Bio Tech's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Vivo Bio Tech (BOM:511509), the current Return-on-Tangible-Equity is 1.79% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vivo Bio Tech (BOM:511509) Overvalued in 2026?
Based on GuruFocus' analysis, Vivo Bio Tech stock appears to be undervalued.
The current stock price of ₹23.57 is trading 22.6% below its estimated GF Value™ of ₹30.45.
GuruFocus considers Vivo Bio Tech to be Modestly Undervalued.
Key valuation signals for BOM:511509:
Return-on-Tangible-Equity: 1.79% (87% below median its 10-year median of 13.68)
GF Value™: ₹30.45 vs. price of ₹23.57 (22.6% below fair value)
No single metric tells the full story. See the BOM:511509 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vivo Bio Tech Ltd offers drug development and discovery services to pharmaceutical and biotech companies. The company offers services in the areas of In vitro, In vivo, toxicity studies, pharmacological investigations, pharmacokinetic and toxicokinetic studies. It offers services in the areas of pharmacology, toxicology, pathology, analytical chemistry, lab animal diagnostics, custom model generation, custom breeding, surgical models, and molecular biology.
64GF Score
Get the complete analysis for BOM:511509
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:511509 has been successfully added to your 
